Loading...
XKRX
290650
Market cap1.06bUSD
Dec 05, Last price  
68,800.00KRW
1D
5.04%
1Q
63.23%
IPO
653.28%
Name

L&C Bio Co Ltd

Chart & Performance

D1W1MN
XKRX:290650 chart
P/E
11.06
P/S
21.65
EPS
6,218.42
Div Yield, %
—
Shrs. gr., 5y
2.78%
Rev. gr., 5y
19.85%
Revenues
72.09b
+4.68%
8,999,068,63011,821,737,96017,900,842,82021,240,893,56029,151,665,34032,972,771,33045,677,013,79052,572,492,15068,869,546,32072,093,323,000
Net income
141.06b
+191.69%
1,202,060,7501,981,143,8903,753,072,9505,207,676,9107,250,030,33010,813,093,57013,814,433,3004,544,175,31048,361,014,774141,064,261,000
CFO
-8.57b
L-29.39%
-1,327,717,960-185,353,5703,818,116,8103,845,774,8206,430,855,6207,419,054,67010,906,636,010-6,075,796,000-12,132,875,370-8,566,587,000
Dividend
Dec 27, 2023100 KRW/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

L&C BIO Co., Ltd. operates as a research and development company in tissue regeneration medicine. It offers human tissue, medical device, and cosmetics products. The company was founded in 2011 and is headquartered in Seongnam, South Korea.
URL
http://www.lncbio.co.kr/
IPO date
Nov 01, 2018
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT